Investor Presentaiton
Investment Rationale
Sustainable business model with strategic focus on regulated markets with markets of
USA, UK, Australia, New Zealand, Canada contributing to c. 95% of total revenues (FY21).
Delivering robust and consistent financial
performance with FY17-FY21 revenue growing at
15.7%, ROCE margin expansion of 2940 bps and a
net cash balance sheet.
USFDA, UKMHRA, TGA-Australia accredited
manufacturing facilities across its key regions
providing for a low-cost base.
Continued focus on R&D investments leading to
a robust pipeline of new developed and under
development products to add onto its existing
300+ approved ANDAS/MAS.
Wide range of product offerings and one of the
most active Indian firms focused on Soft gel.
M
Marksans Pharma Ltd.
Experienced and professional management
team with strong line of operations.
Proven ability to pursue value-accretive and
prudent M&A opportunities and successful
post merger integration
Forward integrated business model with presence across the pharma value chain including
in-house R&D centers, owned and outsourced manufacturing set up and widespread supply
chain and distribution set up through subsidiaries in USA, UK and Australia.
©2021 - Marksans Pharma Limited, All Rights Reserved.
12
122View entire presentation